Key points {#sec12-2050640620924157}
==========

Altered liver function tests are reported in up to half of the patients with COVID-19 infection.Disease severity, pre-existing liver disease and older age present a risk for liver injury.Drug-induced liver injury is an important consideration in patients with COVID-19.Hepatotoxic antiviral medications require careful monitoring of adverse effects.SARS-CoV-2 may directly bind to ACE2 positive cholangiocytes and can cause hepatic injury.Activation of the immune system and 'cytokine storm' may contribute to an immune-mediated process of hepatic injury in COVID-19.The control of cytokine dysregulation at an early stage could be beneficial to curb the disease progression.

Introduction {#sec1-2050640620924157}
============

In the current pandemic coronavirus disease (COVID-19), almost every country in the world has now registered COVID-19 cases, and the confirmed cases have exceeded one million to date. While initial clinical studies, especially from China, the USA and Italy, have highlighted the dominant clinical symptoms including fever, cough, fatigue and shortness of breath, the later research unveiled shreds of evidence on the extrapulmonary manifestations of the disease. These reports highlighted that beyond severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a complicated course of the disease or even viral infection itself can lead to involvement of other organs and multi-organ failure. The liver is the primary organ for detoxification and metabolism, and maintaining an optimal function is imperative to engage all available therapeutic modalities in the treatment of COVID-19. Abnormal liver function requires clinical evaluation, continuous surveillance and, potentially, specific therapy. To support clinical decision making and optimize the outcome in the treatment of COVID-19, it will be crucial to clearly understand the possible mechanisms involved in liver injury. The current review summarizes the pathophysiology and potentially specific role of COVID-19 in liver disease based on the available data and case series published, ahead of print and non-peer-reviewed preprints as of 2 April. The search strategy is detailed in the Supplementary Material online.

Pathophysiological basis of liver injury in patients with COVID-19 {#sec2-2050640620924157}
==================================================================

Emerging data from small clinical case studies have proposed that liver injury in COVID-19 is frequently seen, but the extent and underlying mechanisms remain undetermined. [Figure 1](#fig1-2050640620924157){ref-type="fig"} summarizes the pathophysiological findings, which are discussed below.

![Clinical characteristics and pathophysiology of liver injury from COVID-19.\
ACE2: angiotensin-2 converting enzyme](10.1177_2050640620924157-fig1){#fig1-2050640620924157}

Direct viral effect on the liver {#sec3-2050640620924157}
--------------------------------

The liver exerts a crucial function in host defense against microbes and is involved in most systemic infections as it receives both the portal and systemic circulation. Certain viruses exert a direct cytopathic effect on hepatocytes and cholangiocytes although, in most cases, the pathogenesis seems multifactorial. Yang et al. reported that SARS-CoV could cause direct cytopathic liver injury rather than inducing cellular stress from low oxygen supplies or cytokines as seen in sepsis.^[@bibr1-2050640620924157]^ Autopsy studies in patients revealed that SARS-CoV was detectable in 41% of the liver tissue, with a maximum viral load of 1.6 × 10^6^ copies/g of tissue.^[@bibr2-2050640620924157]^ The pathological findings of liver biopsy specimens from SARS patients showed hepatocellular necrosis, mitoses, cellular infiltration and fatty degeneration. In a recent autopsy analysis of liver tissue from a patient with COVID-19, moderate microvesicular steatosis and mild inflammation in the lobular and portal area was observed. However, this pattern of histological injury is not specific for one etiology but can also be observed during sepsis or drug-induced liver injury (DILI).^[@bibr3-2050640620924157]^

The role of cholangiocytes in COVID-19 {#sec4-2050640620924157}
--------------------------------------

Similar to SARS-CoV, SARS-CoV-2 uses the angiotensin-2 converting enzyme (ACE2) receptor protein to attack the host system.^[@bibr4-2050640620924157]^ The cell entry receptor, ACE2, is widely expressed across the human body, including the lungs (type II alveolar cells), gastrointestinal tract (esophageal epithelial cells and absorptive enterocytes of ileum and colon), hepatobiliary system (hepatocytes and cholangiocytes), cardiovascular system (myocardial cells), the renal system (proximal tubule cells and urothelial bladder cells) and the pancreas.^[@bibr5-2050640620924157]^ Recent studies have observed that ACE2 expression in the cell clusters of cholangiocytes was significantly higher than that in the hepatocytes population (59.7% *vs*. 2.6%).^[@bibr6-2050640620924157]^ The authors conclude that SARS-CoV-2 may directly bind to ACE2 positive cholangiocytes, but not hepatocytes, to exert a cytopathic effect. Cholangiocytes are involved in many aspects of liver physiology, including regeneration and adaptive immune response mechanisms, and the disruption of cholangiocyte function can cause hepatobiliary damage. This is supported by cholestatic markers, including gamma-glutamyl transferase (GGT), that can be found in some, but not all, case series of COVID-19.^[@bibr7-2050640620924157][@bibr8-2050640620924157]--[@bibr9-2050640620924157]^ Notably, a recent review reported unpublished data with GGT elevations in 54% of cases.^[@bibr8-2050640620924157]^ In a human organoid model of liver ductal organoids, permissiveness to SARS-CoV-2 infection was observed. Here viral infection impaired the barrier and bile acid transporting functions of cholangiocytes through dysregulation of genes involved in tight junction formation and bile acid transportation, supporting the susceptibility of cholangiocytes in SARS-CoV-2-related liver injury.^[@bibr10-2050640620924157]^

Activation of the immune system in COVID-19 {#sec5-2050640620924157}
-------------------------------------------

Dysregulation of the innate immune response can be one aspect of liver injury in COVID-19. Patients with COVID-19 exhibit marked activation of inflammatory markers, including abnormal levels of C-reactive protein (CRP), lymphocytes, neutrophils and cytokines, in particular interleukin-6 (IL-6).^[@bibr8-2050640620924157]^,^[@bibr11-2050640620924157][@bibr12-2050640620924157]--[@bibr13-2050640620924157]^ These mechanisms may contribute to pulmonary and extrapulmonary injuries^[@bibr12-2050640620924157]^,^[@bibr14-2050640620924157]^ and the control of cytokine dysregulation at an early stage could be beneficial to curb the disease progression.^[@bibr15-2050640620924157]^

Hepatic inflammation involving activation of innate immune cells and the release of cytokines is a well-established driver of liver injury from various causes.^[@bibr16-2050640620924157]^ In some of the available case series of COVID-19, a correlation between lymphopenia and liver injury was observed and CRP ≥20 mg/L and a lymphocyte count \<1.1 × 10^9^/L were independent risk factors for liver injury. Notably, lymphopenia in COVID-19 studies was reportedly observed in 63% to 70.3% of patients and those with lower lymphocyte counts more susceptible to fatal outcomes.^[@bibr11-2050640620924157]^

Clinical evidence {#sec6-2050640620924157}
=================

Elevated liver function tests (LFTs) in COVID-19 {#sec7-2050640620924157}
------------------------------------------------

More than 20 publications to date reported abnormal levels of aminotransferases in patients with COVID-19.^[@bibr7-2050640620924157]\--[@bibr8-2050640620924157]^,^[@bibr11-2050640620924157][@bibr12-2050640620924157]--[@bibr13-2050640620924157]^,^[@bibr17-2050640620924157]\--19,21,23\--27,[@bibr17-2050640620924157][@bibr18-2050640620924157][@bibr19-2050640620924157][@bibr20-2050640620924157][@bibr21-2050640620924157][@bibr22-2050640620924157][@bibr23-2050640620924157][@bibr24-2050640620924157][@bibr25-2050640620924157]--[@bibr26-2050640620924157],[@bibr26-2050640620924157],[@bibr26-2050640620924157]^ A recent systematic review and meta-analysis on LFT abnormalities provided a pooled elevation of aspartate aminotransferase (AST) in 33.3% and alanine aminotransferase (ALT) in 24.1% of cases.^[@bibr39-2050640620924157]^ Various investigators across different studies reported a correlation between the severity of COVID-19 and the degree of liver dysfunction.^[@bibr8-2050640620924157]^,^[@bibr11-2050640620924157]^,^[@bibr25-2050640620924157]^ In one retrospective study, one patient experienced severe hepatitis with ALT of 7590 U/L and AST of 1445 U/L.^[@bibr17-2050640620924157]^ In a report from Shanghai, 50.7% of patients presented with elevated LFTs at the time of hospitalization. Interestingly, these were more likely to have a moderate-to-high-grade fever when compared with the patients with normal LFT (44% *vs*. 27.4%; *p* = 0.035).^[@bibr7-2050640620924157]^ On the other hand, mild and moderate cases experienced only discrete abnormal LFT values. These reports support the concept that the disease severity and an older age predispose to more severe liver injury from COVID-19. Based on these case series, patients with severe COVID-19 and pre-existing liver conditions^[@bibr8-2050640620924157]^ -- but also elderly patients^[@bibr11-2050640620924157]^ -- should undergo surveillance and individually tailored therapeutic approaches for potential liver injury.

A recently published article by Bangash et al. argues after careful review of seven relevant studies that elevated ALT and AST may not necessarily be of hepatic origin alone. The authors have given a timely reminder that it is common for other respiratory viruses to create similar LFT elevations^[@bibr28-2050640620924157]^ and thus more prospective data related to the clinical relevance COVID-19 and liver injury is required.

The previous pathogenic coronaviruses, such as SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), were also reported to manifest with elevated levels of ALT and AST.^[@bibr39-2050640620924157]^ More generally, non-hepatotropic viral infections may affect the liver and induce hepatitis or fulminant acute liver failure. However, in the majority of cases, recovery from viral illness is often sufficient to resolve liver injury.^[@bibr40-2050640620924157]^

Like in SARS-CoV and MERS-CoV infections, abnormal levels of albumin and lactate dehydrogenase (LDH) were also reported in SARS-CoV-2 infection, with the maximum of 98% and 76% of the patients affected as reported in the study by Chen et al.^[@bibr17-2050640620924157]^ It is important to remember that LDH and AST elevation could be from muscle damage and not necessarily reflect liver injury.

DILI {#sec8-2050640620924157}
----

The current armory of therapeutic agents explored against SARS-CoV-2 includes several antiviral agents, supportive therapy and trials of alternative medicines in many regions of the world. Given the fact that the liver is involved in the metabolism of many drugs, including nucleoside analogs and protease inhibitors that are currently used to treat COVID-19, hepatotoxicity from these drugs can arise.

A recent randomized controlled trial of lopinavir and ritonavir in severe COVID-19 reported that elevated levels of AST, ALT and total bilirubin occurred as adverse effects in a few patients.^[@bibr41-2050640620924157]^ Another case series from Wuhan reported that 55.4% of patients experienced liver injuries after treatment with lopinavir and ritonavir.^[@bibr26-2050640620924157]^ Fan et al. published a retrospective study on COVID-19 and observed that the utilization rate of this drug combination was significantly higher in patients with abnormal LFTs compared with patients without LFT elevations (56.1% *vs*. 25%, *p* = 0.009). In this study, 47.3% of the discharged patients showed elevated LFTs at baseline, and 23.7% developed abnormalities during hospitalization, suggesting emerging liver injury from drugs or during the course of the infection. Importantly, LFT elevation during the hospital stay was associated with prolonged length of hospitalization.^[@bibr7-2050640620924157]^

Chloroquine, an old drug with a potential of repositioning for new treatment indications, has recently been tried in patients infected with SARS-CoV-2. After a profound success in inhibiting viral replication in vitro, concurrent clinical trials (\>20) on chloroquine conducted at 10 hospitals across China have demonstrated superior efficacy in viral control.^[@bibr42-2050640620924157]^ The pharmacodynamic activity of this drug in COVID-19 may involve the arresting of cytokine storms or the activation of CD8+ cells or by preventing endocytosis-mediated uptake of the virus.^[@bibr43-2050640620924157]^ Importantly, hepatotoxicity related to chloroquine or hydroxychloroquine has rarely been reported.

In severe cases of COVID-19 with cytokine release, tocilizumab, an IL-6 antagonist, which is humanized IgG1 monoclonal antibody to the IL-6 receptor, has been used as a potential therapy for SARS-CoV-2. In previous clinical trials for other indications tocilizumab was reported to cause mild elevations of LFTs which were usually transient and commonly resolved within 2--6 weeks from exposure.^[@bibr37-2050640620924157]^

Remdesivir is an experimental antiviral nucleotide analog with broad activity against coronaviruses^[@bibr44-2050640620924157]^ that is currently being trialed for SARS-Cov-2 infection. Safety data from ongoing studies will guide on its use in patients, but so far no reports of liver toxicity have emerged.

Patients with pre-existing liver disease {#sec9-2050640620924157}
========================================

Scare data has been published for COVID-19 infection in patients with pre-existing liver disease. Experience from previous episodes of coronavirus infection can guide on the extent of hepatic involvement and on the management of patients with pre-existing liver disease. In SARS, the highest mortality rates were observed in the elderly and adults with underlying liver disease.^[@bibr45-2050640620924157]^ Therefore, it has to be expected that the patients with COVID-19 are also more vulnerable to hepatic injury.^[@bibr9-2050640620924157]^ In a case series from the Zhejiang province, a prevalence of 11% of underlying liver disease was reported. About half of them experienced symptoms for more than 10 days after the illness onset.^[@bibr21-2050640620924157]^ In another study from Wuhan, 9% of patients had the underlying liver disease of cirrhosis or hepatitis.^[@bibr23-2050640620924157]^ Li et al., who investigated risk factors involved with hepatic injury, stated that two patients had presented with alcoholic liver disease at baseline. One of them had a moderate elevation of ALT (120 U/L) within a week of hospitalization, while the other showed no such abnormalities.^[@bibr11-2050640620924157]^ In the initial cohort described from China, 2.7% exhibited hepatitis B virus infection with no mention of worsening outcomes.^[@bibr26-2050640620924157]^ Therefore, the association of the pre-existing liver conditions with disease prognosis and outcomes in COVID-19 will have to be evaluated by comprehensive data registries which recently started enrolling patients (e.g. COVID-Hep Registry and SECURE-Cirrhosis Registry).

Liver transplant recipients {#sec10-2050640620924157}
---------------------------

Management of post liver transplant recipients during the COVID-19 pandemic presents a special challenge for clinicians because of the limited data available and the crucial need to continue immunosuppressive drugs in these patients, which puts them at risk for more severe courses of COVID-19 infection and possible prolonged viral shedding. Case reports from China did not reveal an increased mortality in organ transplant recipients. Qin et al. reported the first case of SARS-CoV-2 infection in a patient with hepatocellular carcinoma who underwent liver transplantation.^[@bibr29-2050640620924157]^ Lowering immunosuppression to the most acceptable level appears reasonable in infected liver transplant patients, in particular, in the setting of lymphopenia or clinical worsening of infection.^[@bibr46-2050640620924157]^

In addition clinicians have to be aware of drug--drug interactions in the transplant setting. In particular immunosuppressive drugs and ritonavir-boosted antiviral therapies exhibit relevant interactions through CYP34A which lead to increased levels of calcineurin and mTOR inhibitors. Accordingly, chloroquine-based regimes or remdesivir (compassionate use program only) appear to be safe, while boosted protease inhibitors should be avoided (see [Table 2](#table2-2050640620924157){ref-type="table"}). Additionally, preventive strategies in those vulnerable patients include early and prolonged screening with polymerase chain reaction-based testing for patients with early symptoms, a contact history or infection. Personal protective equipment in high risk settings can help to protect this vulnerable patient group.

###### 

Drug--drug Interactions of experimental COVID-19 agents and immunosuppressive therapy.

![](10.1177_2050640620924157-table2)

  Combination                                         Potential risk of interactions                                        Recommendations                                                          
  --------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------
  Calcineurin inhibitor (tacrolimus or ciclosporin)   Atazanavir or lopinavir/ritonavir or chloroquine or hydrocholoquine   Potentially increased exposure of immunosuppressant                      Dose adjustment or close monitoring
  Sirolimus                                           Atazanavir or lopinavir/ritonavir                                     Potentially increased exposure of immunosuppressant                      Avoid coadministration
  Sirolimus                                           Chloroquine or hydrocholoquine                                        Potentially increased exposure of immunosuppressant                      Dose adjustment or close. monitoring
  Tacrolimus or ciclosporin or sirolimus              Tocilizumab                                                           Potentially decreased exposure of immunosuppressant                      Interaction of weak intensity; additional action/monitoring or dose adjustment unlikely required
  Mycophenolate                                       Lopinavir/ritonavir                                                   Potentially increased or decreased exposure of mycophenolate             Dose adjustment or close monitoring
  Basiliximab                                         Tocilizumab                                                           Enhanced immunosuppressive effect                                        Avoid coadministration
  Azathioprine                                        Ribavarin                                                             Myelotoxicity due to accumulation of 6-methylthioinosine monophosphate   Dose adjustment or close monitoring
  Azathioprine                                        Tocilizumab or interferon-β                                           Additive hematological toxicity                                          Caution required; close monitoring of hematological parameters

Modified from Liverpool Drug interactions Group (5 April 2020; <https://www.hep-druginteractions.org/>).

Summary and clinical recommendations {#sec11-2050640620924157}
====================================

Liver function abnormalities -- predominantly AST elevation -- in COVID-19 appear to be frequent but not severe in most cases. Direct viral hepatotoxicity, DILI, 'bystander effects' during a systemic viral infection and potentially sepsis, or exacerbation of an underlying liver disease have to be considered. Ex vivo studies offer that SARS-CoV-2 can selectively target the liver, in particular cholangiocytes through ACE2, and thus hepatobiliary injury appears plausible. Irrespective of the mechanisms involved in the hepatic injury of patients with COVID-19, activation of the immune-mediated pathway seems to be critical. Special high risk populations require close monitoring. These include the elderly population, patients with end-stage liver disease and liver transplant recipients. Symptomatic treatment with acetaminophen and avoidance of non-steroidal anti-inflammatory drugs in cirrhosis is recommended. Cautious use of antiviral agents in patients with decompensated liver disease and drug--drug interactions in post liver transplant patients has to be considered. As emphasized by a recent position paper of the European Study of Liver Disease, elective procedures and routine tests should be postponed according to the risk--benefit at the given time. On the other hand, emergency medical care needs to be done with appropriate measures to prevent infection.^[@bibr46-2050640620924157]^
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###### 

Abnormalities in hepatobiliary function and inflammatory markers along with the proposed theories of hepatic injury in COVID-19.

![](10.1177_2050640620924157-table1)

  Ref. no.   Author (et al.)   Publication type   Publication date   Study type                                                 No. of patients with COVID-19                                 Pre-existing liver diseases                                                                                                                Hepatobiliary function markers                                                                                                                                                                        Inflammatory markers (and other relevant blood tests)                                                                                                                                                                  Proposed possible theories of hepatic injury
  ---------- ----------------- ------------------ ------------------ ---------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  12         Huang C           Published          24 Jan 2020        Prospective case series                                    41                                                            Chronic liver disease in one patient                                                                                                       AST (max., 48.0 U/L) increased in 37%, more in the ICU group                                                                                                                                          73% had LDH \>245 U/L (max., 408 U/L)37% had LYM ≥1.0 × 10^9^/L (max., 1.1 × 10^9^/L)                                                                                                                                  Overall disease exacerbation: Cytokine storm
  17         Chen N            Published          30 Jan 2020        Retrospective case series                                  99                                                            No histories of hepatic diseases reported                                                                                                  ALT, AST, and TIBIL increased in 28%, 35%, and 18% of patients                                                                                                                                        CRP, ESR, IL-6, and LDH elevated in 86%, 85%, 52%, and 76% of patientsALB and LYM reduced in 98% and 35% cases, respectively                                                                                           Overall disease exacerbation: Damage to T lymphocytes
  22         Wang D            Published          7 Feb 2020         Retrospective case series                                  138                                                           Chronic liver disease in 2.9% of patients                                                                                                  No significant liver abnormalities                                                                                                                                                                    LYM (Median: 0.8 × 10^9^/L) reduced in 70.3% cases, and LDH (Median: 261 U/L) increased in 39.9% of patients                                                                                                           Overall disease exacerbation: Cytokine storm induced by virus invasionSustained inflammatory response
  26         Cai Q             Preprint           19 Feb 2020        Retrospective case series                                  298                                                           2.7% had liver disease (details unspecified) Severe cases were associated with underlying diseases                                         14.8% experienced liver injury (ALT (max., 59.5 U/L) and AST (max., 65 U/L): 8.7 %, respectively)                                                                                                     CRP (max., 47.13 mg/dL) increased in 70% casesIL-6 (max., 28.72 ng/L) increased in 76% of patientsESR (max., 50 mm/h) increased in 60.9%LYM (min, 0.91 × 10^9^/L) reduced in 38.3%                                     Overall disease exacerbation: Inflammatory factor storm
  21         Xu XW             Published          19 Feb 2020        Retrospective case series                                  62                                                            11% had underlying liver disease (details unspecified) About half of them experienced symptoms for more than 10 days after illness onset   AST (max., 32 U/L) increased in 16% of patients                                                                                                                                                       42% showed LYM reduction27% had LDH \>245 U/LQuinolones and β-lactams administered if CRP \>30mg/L                                                                                                                     None described
  18         Yang X            Ahead of Print     24 Feb 2020        Retrospective case series                                  52                                                            No histories of hepatic diseases reported                                                                                                  29% had liver dysfunction (no specifics given)                                                                                                                                                        LYM reduced in 85% cases                                                                                                                                                                                               None described
  23         Shi H             Published          24 Feb 2020        Retrospective case series                                  81                                                            Hepatitis or liver cirrhosis in 9% of cases                                                                                                AST (\>40 U/L) increased in 53% of patients, lower in asymptomatic patients                                                                                                                           LYM (≥1.0 × 10^9^/L) increased in 67%.CRP (Mean: 6.9 mg/L) was lower in asymptomatic patients                                                                                                                          None described
  27         Cao W             Preprint           25 Feb 2020        Retrospective case series                                  128                                                           None described                                                                                                                             ALT (Mean: 43.87 IU/L) and AST (Mean: 44.13 IU/L) increased in severe cases                                                                                                                           LYM (Mean: 0.67 × 10^9^/L) reduced and CRP (Mean: 37.92 mg/L) increased in severe cases                                                                                                                                None described
  19         Zhang B           Preprint           27 Feb 2020        Retrospective case series with the data of non-survivors   82                                                            Liver disease in 2.4% cases                                                                                                                ALT (\>40 U/L), AST (\>40 U/L), and TBIL (\>20.5 mmol/L) increased in 30.6%, 61.1%, and 30.6% cases                                                                                                   LYM (\<1.0 × 10^9^/L), ALB (\<40 g/L) and CD8+ cells (\<220 × 10^9^/L) reduced in 89.2%, 77.8%, and 98.3% cases, respectivelyLDH (\>250 U/L) and CRP (\>10 U/L) elevated in 93.2% and 100% of patients, respectively   Overall disease exacerbation: Viral invasion of organsInflammatory factor elicitationPerturbation of immune system
  25         Guan WJ           Ahead of print     28 Feb 2020        Retrospective case series                                  1099                                                          Hepatitis B in 2.1% of patients                                                                                                            Increase of AST (\>40 U/L) in 22.2%, ALT (\>40 U/L) in 21.3%, and TBIL (\>17.1µmol/L) in 10.5%                                                                                                        Elevation of CRP (≥10 mg/L) and LDH (≥250 U/L) in 60.7% and 41.0%, respectively                                                                                                                                        None described
  7          Fan Z             Preprint           28 Feb 2020        Retrospective case series                                  148                                                           None described                                                                                                                             50.7% of patients had liver function abnormalities at admission21.6%, 18.2%, 17.6%, 6.1%, and 4.1% patients had elevated AST, ALT, GGT, TBIL, and ALP, respectively.                                  35.1% showed LDH elevationCD4+ and CD8+ T cells decreased and CRP increased in abnormal liver function group                                                                                                           Drug-induced inflammatory factor stormViral infection of the liver
  8          Zhang C           Published          4 Mar 2020         Review with a description of unpublished case series       56                                                            3.6% of patients had pre-existing liver diseases (details unspecified)                                                                     28.6% of cases had abnormal liver functionsOne fatal case with evaluated liver injury (ref. no. 3)                                                                                                    None described                                                                                                                                                                                                         Direct viral infection of liver cellsDrug-induced immune dysfunction
  24         Huang Y           Preprint           5 Mar 2020         Retrospective case series with the data of non-survivors   36                                                            No histories of hepatic diseases reported                                                                                                  ALT, AST and TBIL increased in 13.3%, 58.1%, and 12.9% of patients, respectively                                                                                                                      LYM and ALB decreased in 70.6% and 80.6% cases, respectively. LDH and IL-6 increased in all patients. CRP increased in 96.97% of cases                                                                                 None described
  11         Li L              Preprint           10 Mar 2020        Retrospective case series                                  85                                                            Hepatitis B, alcoholic liver disease, and fatty liver disease (*n*=2 in each category)                                                     24.7% had ALT elevation at admission                                                                                                                                                                  CRP ≥20mg/L and LYM count \<1.1 × 10^9^/L were independent risk factors for hepatic injury. ALB (Mean: 33.4 g/L) in ALT elevated group was significantly lower                                                         Inflammatory cytokine stormDeterioration of the disease with a dynamic process
  13         Cui Y             Ahead of print     17 Mar 2020        Case report of an infant                                   1                                                             A healthy infant with no medical history                                                                                                   ALT (84 IU/L), AST (100 IU/L) and TBIL (33.7 µmol/L) elevated                                                                                                                                         CD8+ T cells (2208 cells/µL) and LYM count (5.22 × 10^9^/L) elevated                                                                                                                                                   Overall disease exacerbation: An initial increase in T helper 2 cell response, followed by suppression of inflammatory responses
  9          Xu L              Ahead of print     14 Mar 2020        Review with a comment of unpublished data                  Not described                                                 Not described                                                                                                                              GGT increased in severe cases (values not reported)                                                                                                                                                   Not described                                                                                                                                                                                                          Direct virus-induced cytopathic effectsOvershooting of inflammatory responsesViral hepatitis Drug-induced
  28         Bangash MN        Ahead of Print     20 Mar 2020        Review                                                     --                                                            --                                                                                                                                         --                                                                                                                                                                                                    --                                                                                                                                                                                                                     Virally induced cytotoxic T cellsInduction of a dysregulated innate immune response
  29         Qin J             Ahead ofprint      27 Mar 2020        Case report                                                1                                                             Hepatitis BHCC                                                                                                                             ALT (80 U/L) and AST (132 U/L) declined post-liver transplantation but elevated gradually                                                                                                             LYM reduced to 0.64 × 10^9^/L                                                                                                                                                                                          None described
  30         Xie H             Ahead of print     2 Apr 2020         Retrospective case series                                  79                                                            Patients with previous liver diseases were excluded                                                                                        31.6%, 35.4% and 5.1% of patients had elevated ALT, AST and TBIL, respectively. Median (range) values were 36.5 (17.5--71.5) U/L, 34.5 (25.3---55.3) U/L and 12.7 (8.1--15.4) mmol/L, respectively.   CRP (max., 79.6 µmol/L) and ESR (max., 58 mm/h) increased; while LYM reduced (min., 0.9 × 10^9^/L)                                                                                                                     Overall disease exacerbation: Disease severity
  31         Zhang Y           Ahead of print     2 Apr 2020         Retrospective case series                                  115                                                           Two patients had chronic Hepatitis B (excluded)                                                                                            ALT and AST increased in 9.57% and 14.78% patients, respectively on admission. TBIL elevation was rarely observed. Mean levels higher in severe cases.                                                54.78% had reduced ALB, significantly lower in severe cases. 57.39% had increased CRP, higher in severe cases (80.75±69.18). LDH level (Mean±SD:346.10±257.26) significantly elevated in severe cases                  Dysfunction of immune system
  32         Ding Q            Ahead of print     20 Mar 2020        Prospective case series                                    Five patients who had both COVID-19 and influenza infection   Two patients had Hepatitis B                                                                                                               ALT and AST increased in 40% (each) of cases, respectivelyAcute liver injury occurred in 60% of patients                                                                                              CRP increased in 80%, while LYM reduced in 80% of cases.                                                                                                                                                               None described
  33         Zhao D            Ahead of print     12 Mar 2020        Prospective case series                                    19                                                            Hepatitis B in one patient                                                                                                                 Liver function damage is more frequent in COVID-19 than other pneumonia patients. 27.78% (each) cases had elevated ALT and AST, respectively, while GGT increased in 44.4%                            LDH increased in 31.58% of cases                                                                                                                                                                                       Overall disease exacerbation: Dysregulation of immune system
  34         Feng G            Published          30 Mar 2020        Review article                                             --                                                            --                                                                                                                                         --                                                                                                                                                                                                    --                                                                                                                                                                                                                     Hypoxia-reperfusion dysfunctionSystemic inflammation responseDrug-induced Viral infection of the liverACE2 positive cholangiocytes
  35         Chen H            Published          12 Feb 2020        Retrospective case series                                  9                                                             None described                                                                                                                             33% each had increased ALT and AST, respectively. One had ALT reaching 2093 U/L and AST reaching 1263 U/L                                                                                             56% patients had LYM (\<1.0 × 10^9^ cells/L) reduction75% of cases had elevated CRP (\>10 mg/L)                                                                                                                        None described
  36         Pan F             Ahead of print     13 Feb 2020        Retrospective case series                                  21                                                            None described                                                                                                                             Elevated levels of ALT (max., 107 U/L) and AST (max., 95 U/L) were observed                                                                                                                           Elevated CRP (max., 88.6 mg/L), LDH (max., 377 U/L) and ESR (max., 93 s) were reported                                                                                                                                 None described

ALB: albumin; ALP, Alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GGT: gamma-glutamyl transferase; HCC: hepatocellular carcinoma; ICU: intensive care unit; IL-6: interleukin-6; LDH: lactate dehydrogenase; LYM: lymphocytes; max.: maximum; min.: minimum; TBIL: total bilirubin
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